Compare FLUX & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLUX | BIVI |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3M | 13.3M |
| IPO Year | 2019 | 2013 |
| Metric | FLUX | BIVI |
|---|---|---|
| Price | $0.65 | $1.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 84.9K | ★ 229.4K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,317,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 126.25 | N/A |
| 52 Week Low | $0.66 | $1.06 |
| 52 Week High | $7.55 | $8.34 |
| Indicator | FLUX | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 31.72 | 38.88 |
| Support Level | N/A | $1.22 |
| Resistance Level | $1.18 | $1.51 |
| Average True Range (ATR) | 0.08 | 0.24 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 7.14 | 12.12 |
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.